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EDITORIALS
Diagnosis of peripheral arterial disease of the lower limb
Duplex ultrasound is safe, inexpensive, and accurate enough to guide 
management in most cases
In this week’s BMJ a systematic review by Collins and 
colleagues compares the diagnostic accuracy of duplex 
ultrasound, magnetic resonance angiography, and com�
puted tomography angiography for assessing periph�
eral arterial disease of the lower limb.1 The review also 
evaluates the impact of these assessment methods on 
patient outcomes. It found that contrast enhanced mag�
netic resonance angiography seemed to be more specific 
than computed tomography angiography (better at rul�
ing out stenosis of 50% or more in a lower limb vessel) 
and more sensitive than duplex ultrasound (better at 
ruling in stenosis of 50% or more). Magnetic resonance 
angiography was also generally preferred by patients 
over contrast angiography. So what do these results 
mean for practising clinicians?
In developed countries up to a fifth of the population 
over the age of 60 has lower limb peripheral arterial 
disease, as defined by absent pulses or a reduced ankle 
brachial pressure index. �bout a �uarter of these people      
have symptoms—most commonly intermittent claudi�
cation. This consists of pain in the leg (usually in the 
calf) on walking, as a result of atherosclerotic stenosis 
or occlusion, usually of the superficial femoral artery 
in the thigh.2
Only a small minority of patients with intermittent 
claudication undergo imaging with a view to open sur�        
gical (bypass, endarterectomy) or endovascular (angio� 
plasty, stenting) intervention. Most claudicants are 
treated medically in primary3 or secondary care4—if 
they are treated at all.5 In contrast, most patients with 
severe limb ischaemia (rest pain, tissue loss) undergo 
imaging with a view to interventional treatment, usually 
by means of bypass surgery or angioplasty.6 7
Imaging studies are of little use in peripheral arte�
rial disease unless intervention is being considered and 
the imaging results are likely to influence the choice 
and nature of that intervention. In an era of “high tech” 
medicine we sometimes forget that the purpose of imag�
ing is not just to obtain pleasing pictures but to answer 
specific clinical �uestions that have been thoughtfully 
framed after undertaking a careful history, thorough 
examination, and non�invasive assessments.8 �ot surpri� 
singly, Collins and colleagues found that the availability 
of appropriate clinical data increased the accuracy and 
�uality of imaging interpretation.
The imaging modality should be carefully chosen, in        
an evidence based manner, so as to maximise the �ual�
ity and relevance of information obtained, minimise the 
risk and inconvenience to the patient, and make the best 
use of limited resources. But, as Collins and colleagues 
report, making such a choice can be difficult in people 
with peripheral arterial disease. They could find few 
comparative studies and many had serious methodo�
logical limitations. Most studies had several potential 
sources of bias resulting from the nature of the patient 
population being investigated, the delay between index 
and reference tests, and the inability to blind observers. 
Only one study compared patient outcomes. The rest 
compared diagnostic “accuracy,” which can be hard to 
define in a clinically meaningful way, especially when 
data are presented by arterial segment rather than by 
limb or by patient. �elative sensitivities and specificities,    
often with wide ranges, for various degrees of arterial 
stenosis, most commonly 50%—a level of disease with 
limited biological or clinical relevance—are hard to fac�
tor into everyday clinical decision making. In reality, 
as pointed out by Collins and colleagues, the choice of 
imaging may be more influenced by patient preference 
and tolerance as well as the availability of the test.
When a patient with peripheral arterial disease needs 
diagnostic imaging, it seems sensible to start with the 
simplest and safest modality, which is undoubtedly 
duplex ultrasound.1 2 Only if this proves insufficient 
should more sophisticated, potentially risky, and costly 
tests normally be considered. In practice, this is now     
unusual given the �uality of the machines used and the 
skill of vascular technologists.
Intra�arterial digital subtraction angiography is the 
reference standard, but magnetic resonance angiography 
and computed tomographic angiography can provide 
more information and can be more accurate than ultra�
sound.1 �owever, in many cases the extra information       
and accuracy has little effect on patient management 
and outcome. The only study in the review by Collins 
and colleagues that compared patient outcomes found 
no significant difference between duplex ultrasound and 
intra�arterial digital subtraction angiography.
In summary, the available data,1 supported by every�
day clinical experience, suggest that duplex ultrasound 
is the only imaging test needed in most patients. If ultra�
sound is not sufficient, then most clinicians would prob�
ably choose magnetic resonance angiography rather    
than computed tomographic angiography because it   
is more versatile, more accurate, is not as affected by 
arterial calcification,1 8 and does not involve exposing 
patients to ionising radiation.9 10  
Diagnostic imaging continues to evolve and improve 
at an astonishing rate. There is a growing consensus    
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Provision of primary care in different countries
Priorities of patients should not be overpowered by economic  
and political incentives
Primary care has an important part to play within health�
care systems.1 The World �ealth Organization defines 
the main aim of healthcare systems as the improvement 
of health, but it notes that financing should be fair and 
systems of care ought to respond to people’s expecta�
tions.2 Countries whose healthcare delivery focuses on 
the role of the specialist tend to fare less well in surveys 
that take account of these three goals.3 Primary care 
seems to offer important advantages within healthcare 
systems in terms of cost containment, health status of 
the population, and a range of other health related out�
comes—the value of a strong primary care base within 
national healthcare systems is recognised by W�O.4 
�ow can cross national studies provide insight into the 
optimal organisation of health care?
In this week’s BMJ, Bindman and colleagues5 use data 
from national surveys in �ustralia, �ew Zealand, and 
the United States to compare mix of patients, scope of 
practice, and duration of visits in primary care. Previous 
studies have compared patient morbidity and patients’ 
expectations of care between countries.6 7 This study dif�
fers in that it examines case mix and exposure to primary 
care in three countries using rigorous and innovative ways 
to analyse large nationally representative datasets.
In primary care, length of consultation has been pro�
posed as a marker of �uality of care, with longer consul�
tations increasing patients’ satisfaction and being more 
comprehensive and more responsive to patients’ needs.8 9 
Few studies have reported exposure to primary care in 
populations or have used such a measure to investigate 
differences between groups of individuals with regard 
to the experience or outcome of health care.
In the United Kingdom, a recent national survey of 
primary care provision10 reported a median consultation 
length of 13.3 minutes for general practitioners in 2003. 
UK patients have an average of 4.5 consultations each 
year, so these figures imply a per capita annual exposure 
to primary care physicians of around 60 minutes each 
year—an increase of 28% in just five years.11 Bindman 
and colleagues highlight a substantial variation in such 
exposure between the three countries they studied—from 
29.7 minutes each year in the US to 83.4 minutes each 
year in �ustralia.
Similar methods to those used by Bindman and col�
leagues to define case mix have been used to investigate 
the relative contribution of social class and case mix in 
modelling the use of home visits in primary care set�
tings.12 The methodological approach used in the current 
study to assess differences in case mix is sophisticated; it 
draws on a diagnostic coding system developed at Johns 
�opkins �ospital, which has been validated for use in 
primary care. It has the potential to compare case mix in 
primary care in countries that extensively use morbidity 
coding systems, such as those of the International Clas�
sification of Disease or �E�D coding system.
� limitation of Bindman and colleagues’ study is 
that only administrative or preventive care codes were 
recorded in up to 20% of consultations, and these were 
excluded from the analysis. While the role that doc�
tors play in society varies in different countries, the 
authors are right to note that such consultations should 
be included in the overall assessment of case mix. This 
would enhance the generalisability of the findings and 
provide a more comprehensive overview of the contri�
bution of primary care to the healthcare system within 
the country.
It may be surprising to general clinicians providing 
“comprehensive” first line care that 75% of the work�
load of US primary care physicians’ comprises just 46 
conditions. �lso, this number rose to only 57 conditions 
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that invasive techni�ues should not be used to visualise 
the arterial system unless a therapeutic intervention is 
intended. Thus, diagnostic intra�arterial digital subtrac�  
tion angiography is likely to become a thing of the past,          
with open and endovascular treatments for peripheral 
arterial disease being planned almost exclusively on the 
basis of duplex ultrasound and, where necessary, mag�
netic resonance angiography.11 12
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for family doctors in �ew Zealand, a country that is 
much more orientated towards primary care than the 
US, and which has healthcare structures similar to those 
of the UK �ational �ealth Service. Some substantial 
differences were seen between national populations in 
primary care case mix—women in the US had lower 
rates of attending primary care for gynaecological prob�
lems, but attendance for endocrine and cardiovascular 
problems was much higher in the US than in �ustralia 
and �ew Zealand. Such observations may reflect dif�
ferences between countries in access to care and in the 
gatekeeping role of family doctors, but they may also 
result from cultural differences between populations 
in their interpretation of symptoms and in their use of 
health services.
Even in Western healthcare systems, ine�ualities 
in health status and experience of care exist between 
individuals. S�uandering of resources through failure 
to provide a strong primary care base within national 
health systems is likely to reinforce divisions within soci�
ety, worsen the health status of individuals, and create 
a healthcare system that is unresponsive to the needs of 
the population. Cross national comparative studies have 
the potential to inform the development of services, but 
they need to take account of the beliefs and values of the 
people served as well as the ambitions and resources of 
their health professionals and politicians.
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Transition of care in children with chronic disease
Healthcare teams need to adapt to change as much as patients and their families
In this week’s BMJ, a woman with cystic fibrosis 
describes her experience of living with the disease from 
childhood to adulthood.1 �mong the many challenges 
she describes is the “rocky road” of transition from pae�
diatric to adult health care. She says that she would have  
given anything to attend a transition clinic when she was 
16 years old, instead of going straight to an adult clinic 
at another hospital.
Cystic fibrosis was previously considered a lethal dis�
order of childhood, but as survival improves, the need 
for continuous care into adulthood becomes more 
important. For the past two decades the global cystic 
fibrosis community has recognised the importance of 
transferring care from paediatric to adult services, and 
has set an example for services in other chronic condi�
tions to follow.2
Transition to adult care for any child with a chronic 
life limiting illness should not consist of just transfer to 
a doctor who treats adults. It should be a clinical and 
psychosocial process. �dolescence is a time of great 
change—a normal journey of transition from childhood 
to adulthood. It is a difficult and exciting time as shifts 
occur in emotional attachments, autonomy, self iden�
tity, sexuality, physical shape, philosophy of life, and 
vocation. For those with a chronic illness, this devel�
opmental stage is complicated further as the teenager 
takes responsibility for care and faces problems associ�
ated with morbidity, mortality, and limitations to life’s 
options. Coping with these extra problems on top of 
the normal challenges of adolescence is an immense 
challenge, which is made worse by being cut off by the 
paediatric care team that the patient knows and trusts.
Fundamental differences exist between paediatric 
and adult chronic care. Paediatric care is often multidis�
ciplinary, prescriptive, and family focused. It re�uires 
parental direction and consent. �dult care tends to be 
patient focused, and it encourages autonomy in making 
decisions about treatment and life choices. Professionals 
in adult care are familiar with the difficulties associated 
with sex, pregnancy, work, and raising a family in the 
context of chronic ill health.3
� successful transition process has defined stages. 
Firstly, the needs and benefits of a move to adult care 
are explained and discussed with the young adult patient 
and the parents. � combined clinic is then held where 
the patient and family meet with the “receiving” team 
for a multidisciplinary handover. �n orientation tour 
of the adult centre is an important part of the journey. 
Finally, there is the last goodbye—a visit to ensure that 
all aspects of transition have been covered.4
Surveys show that patients and parents have a positive 
opinion of such transition clinics.5 The parents’ biggest 
concern was whether their child would be able to care 
for their illness independently, although this concern 
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was not always shared by the children.
Transition services have been developed for children 
with other chronic conditions, such as diabetes,6 renal 
disease,7 and complex congenital heart disease,8 in addi�
tion to transplants recipients.9 The principles are similar, 
although local resources and the underlying condition 
determine the details of care.
In the United Kingdom, as in many countries, transi�
tion occurs when patients are between 16 and 18 years 
of age, and it ties in with the educational curriculum and 
social needs. �lthough timing is generally determined 
by age, it may re�uire review in people who are less 
able to care for themselves as a result of mental capacity 
or severe ill health.10
The hurdles for transition medicine lie as much with 
the healthcare teams as with the patients and their fami�
lies. The attitude towards transition and the relationship 
between the paediatric and adult clinics is central to 
success.11 Some paediatric units find it hard to let go of 
children they have looked after for so long. But holding 
on to patients who could benefit from the expertise of 
an adult orientated service causes as many problems as 
treating transition just as an administrative event.
Do we really need a transition service for all chronic 
paediatric conditions? The case for chronic disorders 
with an advancing morbidity and the need for large 
multidisciplinary input is clear and these services have 
been adopted in many countries worldwide, such as 
the United States, �ustralia, South �frica, and many 
countries within Europe.12 �owever, the natural his�
tory of many childhood conditions has changed with 
modern treatment. For example, children with �IV 
find the transition particularly difficult as they move 
into a world with few adolescents and a healthcare envi�
ronment mainly focused on the needs of homosexual 
men.13 �nd for some conditions there are no existing 
adult teams, such as immunodeficiency diseases like 
chronic granulomatous disease.
Some clinical teams and families remain reluctant to 
buy into the concept of transition medicine.14 But the 
considerable financial and emotional input in caring 
for the child with a chronic condition should not be 
lost in a failed transition process. This is not just about 
paediatric teams being unduly precious about the chil�
dren they have steered through 17 difficult years. This 
is about preventing adults looking back and saying, “I 
would have given anything to attend a transition clinic 
when I was 16.”
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In March 2007 the Japanese authorities advised against 
prescribing oseltamivir (Tamiflu, �oche) to adolescents 
aged 10�19 years.1 This unusually severe measure 
resulted from the separate suicides of two 14 year olds 
who jumped to their deaths while taking oseltamivir; 52 
other deaths (14 in children or adolescents) have been 
associated with the same drug. So far, similar action has 
not followed in Europe. When a regulatory authority 
warns doctors not to prescribe a drug but decides 
not to retract its marketing authorisation prescribers 
and patients are entitled to be concerned and a little 
confused.
Oseltamivir is a sialic acid analogue that inhibits 
influenza type � and type B neuraminidase, the viral 
enzyme that allows the release of virus from infected 
cells. Its main licensed indications are the treatment of 
flu, short term postexposure prophylaxis after contact    
with a diagnosed case of flu, and more prolonged (up to 
six weeks) “seasonal” prophylaxis when flu is circulating 
in the community. The licence was extended in 2005 to        
include children aged 1�12 years.
When used to treat otherwise healthy people, oselta�
mivir reduces the duration of symptoms by 1�1.5 days 
if started within 48 hours of first symptoms, irrespective 
of vaccination status, although it may be less effective in 
those with chronic diseases.2�5 It also provides a modest 
reduction in complications such as pneumonia, otitis 
media in children, and hospital admission.4 5 �s postex� 
posure prophylaxis, the protective efficacy of oseltamivir 
was 80�90% in the family contacts of index cases.2 3 6 7 
�s seasonal prophylaxis, the protective efficacy was 74% 
in healthy people aged 18�656 and even higher in frail 
elderly people in residential care.8
The �ational Institute for �ealth and Clinical Excel�
lence advises that oseltamivir should not be prescribed 
for otherwise healthy people because the health gain in 
this group is modest.4 6 �owever, oseltamivir is recom�
mended for treatment and postexposure prophylaxis 
in people who are at increased risk of complications 
because of age or comorbid conditions (box). This 
restricted recommendation in the United Kingdom 
has limited prescription of oseltamivir to only a few 
thousand people.9 In contrast, an estimated 45 million 
patients have received oseltamivir worldwide.1 This has 
been partly boosted by encouragement from the World 
�ealth Organization, as a way to gain familiarity with 
antiviral agents before the outbreak of a pandemic.10 
Several governments have been stockpiling supplies in 
preparation for such an event.
So far, oseltamivir has been thought to be well tol�
erated and safe. The most common adverse effect is 
dose related nausea, which occurs twice as fre�uently 
as with placebo when used as prophylaxis.5 Post� 
licensing monitoring has revealed very rare reports of 
raised liver enzymes and hepatitis and of serious skin 
reactions, including Stevens�Johnson syndrome and 
erythema multiforme.11 �owever, the recent events in     
Japan have prompted a reappraisal.
Before 2007, there had already been more than 100 
reports of neuropsychiatric events (including delirium, 
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convulsions, and encephalitis) with oseltamivir in chil�
dren, almost entirely from Japan, which has the highest 
usage of oseltamivir worldwide. �owever, these disturb�
ing events had to be seen in the context of the millions 
of prescriptions worldwide and the fact that abnormal 
behaviour could also be due to flu or disease related 
complications. Indeed, a Food and Drug �dministra�
tion (FD�) review of clinical trial and postmarketing 
data concluded that these events were not clearly drug 
related but might be related to higher rates of flu related 
encephalitis in Japan.12 Since last �ovember, the FD� 
has re�uired that doctors be warned that patients should 
be closely monitored for signs of abnormal behaviour 
throughout the treatment period and the European 
Medicine Evaluation �gency (EME�) took similar 
steps in February.
The controversy about oseltamivir is a further 
reminder that, although common adverse effects of a 
drug may emerge in prelicensing studies, the detec�
tion of rarer and potentially more serious events has 
to await exposure of large numbers of patients. In the 
UK, oseltamivir is a “black triangle” drug, so it remains 
under more intensive surveillance. Doctors and other 
healthcare professionals should report all minor as well 
as serious adverse events via the yellow card scheme.
In the light of these concerns how should prescrib�
ers proceed? There seems little doubt that oseltamivir 
reduces the number and seriousness of flu episodes 
when used as treatment and prophylaxis. �owever, 
the impact of such events in otherwise healthy people 
is usually modest and of short duration. They should be   
encouraged to use conservative strategies such as resting, 
increasing fluid intake, and taking simple analgesics 
and over the counter symptomatic remedies. In 
people at higher risk of serious complications the potential 
benefit of treatment seems greater, although convinc�
ing evidence about reductions in hospital admission or 
mortality is still awaited. In these groups, vaccination     
still offers a cost effective first line of defence.6
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Patients at high risk of 
complications after flu
•	People	over	65	years	of	
age
•	People	with	chronic	
respiratory	disease	
(including	asthma	and	
chronic	obstructive	
pulmonary	disease)
•	Patients	with	
cardiovascular	disease	
(excluding	those	with	
hypertension	only)
•	Patients	with	chronic	
renal	disease
•	Immunocompromised	
patients
•	People	with	diabetes	
mellitus
Rosiglitazone and implications for pharmacovigilance
Postsurveillance data should be systematically collected and publicly available
On 21 May 2007, the New England Journal of Medicine 
published a meta�analysis of 42 trials of rosiglitazone 
(�vandia, GlaxoSmithKline) for treating type 2 diabe�
tes mellitus. It found that the drug was associated with 
an increased risk of myocardial infarction (odds ratio 
1.43; 95% confidence interval 1.03 to 1.98; P=0.03) and 
death from cardiovascular causes (1.64; 0.98 to 2.74; 
P=0.06).1
�osiglitazone, a thiazolidinedione, is an agonist at the 
peroxisome�proliferator activated receptors in cell nuclei. 
These receptors modulate the expression of a host of 
genes, and glycaemic control is achieved primarily 
through increased insulin sensitivity in peripheral tissues. 
�osiglitazone was approved by the US Food and Drug 
�dministration (FD�) in 1999 and by the centralised 
process of the European Medicines �gency (EME�) in 
2000. Its popularity has increased steadily, with more 
than one million prescriptions written in the one year 
period ending March 2006 in England alone—a 22% 
increase over the previous year.2 �owever, the recently 
published meta�analysis raises serious �uestions about 
the drug’s safety.
Meta�analyses have uni�ue strengths and weaknesses 
and this one is no exception.3 Its singular strength is the 
statistical power generated by data on 15 560 patients 
from published and unpublished trials. �owever, it 
includes clinically heterogeneous trials and criteria used 
by individual trials to classify adverse events are some�
what unclear. Only summary data are available in the 
public domain—for example, whether or not a person 
had a myocardial infarction, not when it occurred—which 
makes time to event analyses impossible. �lso, the total 
number of adverse events was small, so that misclassifi�
cation of a few events could alter the conclusions.
In response to the concerns raised by this meta�analy�
sis, an unplanned interim analysis of a large, manufacture 
sponsored, randomised, open label, non�inferiority trial 
specifically designed to investigate the cardiovascular 
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safety of rosiglitazone was recently released.4 Compared 
with patients taking metformin and a sulphonylurea, 
people taking a regimen that included rosiglitazone had 
no significant increase in the risk of myocardial infarc�
tion (hazard ratio 1.16, 0.75 to 1.81), although they had       
a significantly increased risk of heart failure (2.24, 1.27  
to 3.97). When these new data are added to the trials in           
the previous meta�analysis, rosiglitazone is associated 
with an increased risk of myocardial infarction (odds 
ratio, 1.33; 1.02 to 1.72).5
To summarise, the meta�analyses show a significantly 
increased risk for myocardial infarction, whereas several 
individual prospective trials do not. More data would 
certainly help to clarify the matter, but the emerging 
safety concerns �uestion the prudence of continuing 
ongoing trials. �otwithstanding the ethical concerns, 
it may be impossible to prevent an exodus of patients 
from these trials in light of the ongoing “trial by media” 
of the drug. 
The broader �uestion is how this reflects on regulatory 
processes used to monitor drug safety. Postmarketing 
surveillance, or pharmacovigilance, remains the weak�
est link in the regulatory process on both sides of the 
�tlantic. The current approach—the FD�’s adverse event 
reporting system and the European EudraVigilance pro�
gramme—relies heavily on passive surveillance, and it 
is based on reports of unusual adverse events from con�
sumers, practitioners, manufacturers, and national regu�
latory authorities. �t best, this creates a case series, one 
of the weakest forms of epidemiological evidence,6 that 
would be insensitive to an increase in common events 
like myocardial infarcts in diabetics. 
�lternatively, the regulatory authorities may re�uire 
systematic phase IV trials after market authorisation, 
but these are often not completed in a timely manner. 
In the United States, completion dropped from 62% 
in the 1970s to 24% in recent years,6 and the FD� is 
ill e�uipped to act against defaulters. �s of September 
2006, 930 (74%) of the 1259 postmarket studies were 
pending or delayed.7
This results in a fractured regulatory process, where 
the preapproval phase is marked by stringent re�uire�
ments for safety and efficacy data, but performance in 
postmarketing surveillance falls short of the standards 
the agencies set for themselves. This is exemplified by 
the case of rosiglitazone. �osiglitazone comes from a 
family of drugs with well documented side effects,8 9 
and itself is associated with increased heart failure, anae�
mia, and raised low density lipoprotein concentration. 
�owever, postmarketing safety data seven years after 
regulatory approval consist of a patchwork of hetero�
geneous manufacturer sponsored trials, many of which 
are unpublished. Of note, a similar meta�analysis sub�
mitted by the manufacturer to the EME� and the FD� 
in �ugust 2006 showed an increased risk in ischaemic 
events (hazard ratio, 1.31, 1.01 to 1.70).     10 The EME� 
updated the product label of the drug,11 but no specific 
communication to healthcare professionals was issued. 
The FD� did neither.
The system needs to be fixed. The Institute of 
Medicine recommends a life cycle approach to drug 
evaluation.12 This would involve a systematic effort to 
monitor the safety and efficacy of a drug before and 
after approval using data from well designed clinical 
trials to inform ongoing risk�benefit analyses. This 
process could be made more systematic by re�uiring 
regulatory authorities to periodically and independently 
re�evaluate all data gathered after approval for all new 
molecular entities—particularly drugs with high sales.
In addition, the lack of transparency in the current 
system needs to be dealt with. There should be a legal 
re�uirement for all phase II�IV trials to be registered 
in a centralised database, such as the �ational Library 
of Medicine’s clinicaltrials.gov or an e�uivalent. Com�
plete datasets from these trials, systematic analyses of 
the results, and reports of periodic evaluations by the 
regulatory agencies must be publicly available. 
� radical change is needed in the culture of existing 
regulatory institutions that regard postmarketing surveil�
lance as their secondary mandate. This will re�uire sys�
tematic rethinking of the existing regulatory and funding 
processes, and expediting changes currently in the pipe�
line.13 Progress will entail empowering the regulatory 
agencies with additional authority and resources.
The manufacturer and the FD� will share the spot�
light as congressional investigation into the matter starts. 
In the meantime, what are the implications for patients 
currently on rosiglitazone? Doctors will need to revisit 
the indication for the drug on a case by case basis, bear�
ing in mind that several alternatives are cheaper, sup�
ported by robust evidence, and now perhaps safer.14 
The decision to switch drugs must be tempered by the 
fragility of the available evidence and the risks associ�
ated with altering patients’ medical regimens. �eedless 
to say, the ongoing use of rosiglitazone merits careful 
deliberation.
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